Novel Werner Syndrome RecQ DNA Helicase (WRN) Inhibitors for Cancer Treatment

ACS Medicinal Chemistry Letters 2026 Open access

Read full text
Authors: Xin Zhou, Steven H. Liang
DOI: 10.1021/acsmedchemlett.5c00746
Cited by: 0
References: 6

Abstract

The Werner Syndrome RecQ DNA helicase (WRN) plays a crucial role in DNA metabolism and genome stability. This patent collectively demonstrates the synthesis, composition and formulation about novel WRN inhibitors featuring bicyclic heterocycles for cancer treatment.

Fields of Study & Subjects

DNA Repair Mechanisms DNA and Nucleic Acid Chemistry Carcinogens and Genotoxicity Assessment

Publication details

Journal / source
ACS Medicinal Chemistry Letters
Publisher
American Chemical Society (ACS)
Volume
17
Issue
2
Pages
284–286
Publication date
4 January 2026
Language
EN